Shanghai Pharmaceuticals Holding Co., Ltd. (SH Pharma) released its unaudited interim results for the six months ended 30 June 2026.

Revenue edged up 4.15 % year on year to RMB 147.47 billion, driven by an 8.44 % rise in pharmaceutical manufacturing sales to RMB 13.19 billion and a 3.75 % increase in pharmaceutical services revenue to RMB 134.28 billion.

Net profit attributable to shareholders fell 21.40 % to RMB 3.50 billion. The decline reflects a high comparison base in the prior-year period and lower investment gains; investment income dropped 74.60 % to RMB 0.83 billion. Adjusted for non-recurring items, core net profit improved 17.98 % to RMB 2.48 billion.

Operating cash flow strengthened markedly, climbing to RMB 4.45 billion from RMB 0.99 billion a year earlier. R&D expenditure reached RMB 1.05 billion, representing 7.98 % of manufacturing sales.

Total assets stood at RMB 240.77 billion (+3.27 %), while total liabilities were RMB 147.98 billion, leaving a gearing ratio of 22.36 %. Short-term borrowings amounted to RMB 46.53 billion; long-term borrowings were RMB 3.28 billion.

The Board declared an interim cash dividend of RMB 1.00 per 10 shares, totalling RMB 0.37 billion, equivalent to 10.58 % of first-half net profit attributable to shareholders.

SH Pharma reiterated that no material risks have arisen during the period and confirmed no appropriation of funds by controlling shareholders or connected parties. The results remain unaudited and subject to review.